‘Otic Pharma’ Raises $4.3m For Ear Treatment Drug

Global healthcare investment firm OrbiMed Advisors invested $4.3 million in Otic Pharma, an Israeli company that develops foam-based treatments for ear diseases. “Foam-Otic”, according to the company, is considered to be a more efficient drug than ear drops, with lower and less frequent doses. Otic Pharma is about to complete a clinical trial to test the safety and efficacy of its foam treatment. The company is also developing veterinary treatments for pets. The financing will enable it to begin a trial for its veterinary product. View and share